Overview

Dexamethasone-implant for the Treatment of RVO

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate the efficacy and safety of a dexamethasone-implant alone or in combination with bevacizumab. 64 eyes are prospectively investigated. Group 1 (22 CRVO and 16 BRVO) is treated with dexamethasone-implant alone, Group 2 (14 CRVO 12 BRVO) with three consecutive bevacizumab injections followed by a dexamethasone-implant. Recurrences are treated with dexamethasone-implant only. Patients are seen preoperatively and thereafter in monthly intervals. The primary endpoint was BCVA at twelve months.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ludwig-Maximilians - University of Munich

Treatments:

BB 1101
Bevacizumab
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate

Criteria

Inclusion Criteria: maximum duration of symptoms of four months and no known history of
glaucoma or corticosteroid response in the past -

Exclusion Criteria: Glaucoma, Diabetic Retinopathy, prior IVOM, Uveitis

-